BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 33803217)

  • 1. Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease.
    Chang CH; Lin CH; Lane HY
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma d-glutamate levels for detecting mild cognitive impairment and Alzheimer's disease: Machine learning approaches.
    Chang CH; Lin CH; Liu CY; Huang CS; Chen SJ; Lin WC; Yang HT; Lane HY
    J Psychopharmacol; 2021 Mar; 35(3):265-272. PubMed ID: 33586518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings.
    Blennow K; Zetterberg H
    Prog Mol Biol Transl Sci; 2019; 168():3-23. PubMed ID: 31699324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glial activation and inflammation along the Alzheimer's disease continuum.
    Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
    J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning.
    Yilmaz A; Ustun I; Ugur Z; Akyol S; Hu WT; Fiandaca MS; Mapstone M; Federoff H; Maddens M; Graham SF
    J Alzheimers Dis; 2020; 78(4):1381-1392. PubMed ID: 33164929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease.
    Janelidze S; Hertze J; Zetterberg H; Landqvist Waldö M; Santillo A; Blennow K; Hansson O
    Ann Clin Transl Neurol; 2016 Jan; 3(1):12-20. PubMed ID: 26783546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer's disease.
    Hellwig K; Kvartsberg H; Portelius E; Andreasson U; Oberstein TJ; Lewczuk P; Blennow K; Kornhuber J; Maler JM; Zetterberg H; Spitzer P
    Alzheimers Res Ther; 2015 Dec; 7():74. PubMed ID: 26698298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics.
    Gaetani L; Bellomo G; Parnetti L; Blennow K; Zetterberg H; Di Filippo M
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for Alzheimer's disease: current status and prospects for the future.
    Blennow K; Zetterberg H
    J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine Learning Algorithm Helps Identify Non-Diagnosed Prodromal Alzheimer's Disease Patients in the General Population.
    Uspenskaya-Cadoz O; Alamuri C; Wang L; Yang M; Khinda S; Nigmatullina Y; Cao T; Kayal N; O'Keefe M; Rubel C
    J Prev Alzheimers Dis; 2019; 6(3):185-191. PubMed ID: 31062833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.
    Melah KE; Lu SY; Hoscheidt SM; Alexander AL; Adluru N; Destiche DJ; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Gleason CE; Dowling NM; Bratzke LC; Rowley HA; Sager MA; Asthana S; Johnson SC; Bendlin BB
    J Alzheimers Dis; 2016; 50(3):873-86. PubMed ID: 26836182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals.
    Qin T; Prins S; Groeneveld GJ; Van Westen G; de Vries HE; Wong YC; Bischoff LJM; de Lange ECM
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.
    Mattsson N; Insel PS; Palmqvist S; Portelius E; Zetterberg H; Weiner M; Blennow K; Hansson O;
    EMBO Mol Med; 2016 Oct; 8(10):1184-1196. PubMed ID: 27534871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H
    Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.
    Bos I; Vos S; Verhey F; Scheltens P; Teunissen C; Engelborghs S; Sleegers K; Frisoni G; Blin O; Richardson JC; Bordet R; Tsolaki M; Popp J; Peyratout G; Martinez-Lage P; Tainta M; Lleó A; Johannsen P; Freund-Levi Y; Frölich L; Vandenberghe R; Westwood S; Dobricic V; Barkhof F; Legido-Quigley C; Bertram L; Lovestone S; Streffer J; Andreasson U; Blennow K; Zetterberg H; Visser PJ
    Alzheimers Dement; 2019 May; 15(5):644-654. PubMed ID: 30853464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
    Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current state of Alzheimer's fluid biomarkers.
    Molinuevo JL; Ayton S; Batrla R; Bednar MM; Bittner T; Cummings J; Fagan AM; Hampel H; Mielke MM; Mikulskis A; O'Bryant S; Scheltens P; Sevigny J; Shaw LM; Soares HD; Tong G; Trojanowski JQ; Zetterberg H; Blennow K
    Acta Neuropathol; 2018 Dec; 136(6):821-853. PubMed ID: 30488277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.